The criteria, which replace a 2009 version, include clinical scenarios written by cardiologists and cardiac surgeons and provide guidance on when to perform revascularization. The updates were motivated by new clinical gaps in data collection and changes in the medical literature.
Specifically, the new criteria changed percutaneous coronary intervention from inappropriate to uncertain for low-burden left main disease and from uncertain to appropriate for low-burden three-vessel disease.
The American College of Cardiology Foundation, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America and Society of Cardiovascular Computed Tomography jointly developed the criteria.
Related Articles on Hospital Cardiology:
Making Technology Part of a Hospital’s Cardiology Service Line Strategy
Study: Market Competition May Not Benefit Inpatient Heart Failure Care
Infographic: Angioplasties Moving to Outpatient Settings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
